Gilead Sciences

Dernières actualités

Titres dans la langue d'origine de la source.

• 
  More Upside Awaits for Gilead Sciences Stock. Stay Invested. (s'ouvre dans un nouvel onglet)

  2 oct. 2026

• Confluence Investment Management LLC Cuts Position in Gilead Sciences, Inc. $GILD (s'ouvre dans un nouvel onglet)

  MarketBeat · 1 oct. 2026

• 
  Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It (s'ouvre dans un nouvel onglet)

  1 oct. 2026

• ETFs Bought $76.5 Million of Gilead Sciences (GILD) on Sept. 29 (s'ouvre dans un nouvel onglet)

  GuruFocus · 1 oct. 2026

• Gilead Sciences (NASDAQ:GILD) Stock Rating Cut to "Hold" at Zacks Research (s'ouvre dans un nouvel onglet)

  MarketBeat · 1 oct. 2026

• Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors (s'ouvre dans un nouvel onglet)

  Yahoo Finance · 30 sept. 2026

• Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors (s'ouvre dans un nouvel onglet)

  marketwatch.com · 30 sept. 2026

• CAR T-Cell Therapy Market Forecasts Growth from $7.24B (2026) to $13.78B by 2031, Profiling Bristol-Myers Squibb, Gilead Sciences, Novartis & J&J (s'ouvre dans un nouvel onglet)

  30 sept. 2026

• Gilead Sciences (GILD) Tests Its Multi Platform Story On Questions Around Valuation (s'ouvre dans un nouvel onglet)

  Simply Wall Street · 30 sept. 2026

• Gilead Sciences (NDQ:GILD): Fighting HIV/AIDS Is Its Economic Engine (s'ouvre dans un nouvel onglet)

  Stocks Down Under · 29 sept. 2026

• Gilead Sciences (NASDAQ:GILD) Stock: Stronger HIV Sales Meet Weaker Reported Earnings (s'ouvre dans un nouvel onglet)

  kalkine.ca · 29 sept. 2026

• Former Gilead CIO and CSL Chief Digital & Information Officer Mark Hill Joins Sware Board of Directors (s'ouvre dans un nouvel onglet)

  biospace.com · 29 sept. 2026

• Small Molecule Drug Discovery - Global Strategic Business Report Forecasts Growth from $61.5B (2024) to $100B by 2030, Profiling AstraZeneca, Gilead Sciences, Merck & Pfizer (s'ouvre dans un nouvel onglet)

  29 sept. 2026

• Can Lenacapavir Power Gilead Sciences (GILD)’s Next Growth Phase? (s'ouvre dans un nouvel onglet)

  Yahoo Finance · 28 sept. 2026

• Gilead vs. Intuitive Surgical: Which Healthcare Stock Offers the Better Risk-Adjusted Upside? (s'ouvre dans un nouvel onglet)

  28 sept. 2026

• Gilead Sciences stock last trades at USD 152.43 on September 28, 2026 (s'ouvre dans un nouvel onglet)

  AD HOC NEWS · 28 sept. 2026

• Gilead vs. Danaher: Which Healthcare Growth Story is More Convincing? (s'ouvre dans un nouvel onglet)

  28 sept. 2026

• Gilead vs. Thermo Fisher: Which Life Sciences Stock has the Stronger Growth Outlook? (s'ouvre dans un nouvel onglet)

  28 sept. 2026

• Mirum posts phase 3 hepatitis win for ‘commercially differentiated’ challenger to Gilead, Vir (s'ouvre dans un nouvel onglet)

  Fierce Biotech · 28 sept. 2026

• Can Gilead Sciences (GILD) Justify Its Price As It Raises 2026 Guidance And Dividend? (s'ouvre dans un nouvel onglet)

  Yahoo Finance · 28 sept. 2026

• Gilead vs. Medtronic: Which Healthcare Stock Offers the Better Mix of Growth and Income? (s'ouvre dans un nouvel onglet)

  27 sept. 2026

• Gilead vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward? (s'ouvre dans un nouvel onglet)

  27 sept. 2026

• Gilead or Johnson & Johnson: Is Faster Growth Better than Greater Diversification? (s'ouvre dans un nouvel onglet)

  27 sept. 2026

• Gilead’s HIV Concentration or Pfizer’s Patent Cliff: Which Risk is Easier to Own? (s'ouvre dans un nouvel onglet)

  27 sept. 2026

• Form 4 Gilead Sciences Inc For: 26 September By Investing.com (s'ouvre dans un nouvel onglet)

  Investing.com Nigeria · 27 sept. 2026

• Gilead Sciences, Inc. (NASDAQ:GILD) Stock Has Average Price Target of $158.78 According to Analysts (s'ouvre dans un nouvel onglet)

  MarketBeat · 26 sept. 2026

• Gilead Sciences stock closes at USD 149.69, down 1.11 percent at the close (s'ouvre dans un nouvel onglet)

  AD HOC NEWS · 25 sept. 2026

• UBS Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $175 (s'ouvre dans un nouvel onglet)

  Moomoo · 25 sept. 2026

• Gilead Sciences, Inc. $GILD Stake Decreased by Envestnet Asset Management Inc. (s'ouvre dans un nouvel onglet)

  MarketBeat · 25 sept. 2026

• Gilead Sciences stock heads into the open after a 0.4 percent gain (s'ouvre dans un nouvel onglet)

  AD HOC NEWS · 25 sept. 2026